STEPHENSON BRIAN C purchased $326K of FTH (indirect holdings)
STEPHENSON BRIAN C (Chief Financial Officer) purchased 13,634 indirectly-held shares of Faeth Therapeutics, Inc. (FTH) at an average of $23.92 ($22.95–$24.98, $0.33M total) across 6 trades over 2026-06-29 to 2026-07-01.
How this was made
The 30-second read
Why it matters
Traders may treat the buy as a small sentiment input, but without accompanying guidance, trial results, financing, or regulatory updates, it is unlikely to drive sustained repricing.
Market read
A single insider buy totaling about $326k is disclosed, offering limited incremental information versus the broader company fundamentals.
What to watch
The article does not state the insider’s cost basis, prior holdings changes beyond the post-transaction total, or whether other insiders/large holders acted around the same time.
Background
This is an SEC Form 4 insider transaction for Faeth Therapeutics, Inc., reported as an open-market purchase by the CFO via indirect holdings.
Ticker impact
Faeth Therapeutics CFO Brian C Stephenson bought $326,127 of FTH shares in six trades from 2026-06-29 to 2026-07-01.
Likely limited near-term impact; any effect is sentiment-driven and typically fades unless followed by other news.
The filing is a Form 4 insider transaction with a defined buy size and dates, but it provides no new operational, financial, or regulatory information.
Market effects
No clear sector read-through because the disclosure is company-specific and lacks broader industry/regulatory context.
None indicated.
None indicated.
Counterpoint
Indirect holdings and a lack of a 10b5-1 plan do not guarantee conviction; purchases can be driven by liquidity planning, compensation mechanics, or diversification constraints.
Key entities
- issuerFaeth Therapeutics, Inc.
Subject of the Form 4 insider transaction; CFO reported open-market purchases of FTH shares.
- insiderBrian C Stephenson
Chief Financial Officer who purchased shares; filing reports indirect holdings and post-transaction share count.